ClinicalTrials.gg
CompletedNCT00402168Updated Jan 5, 2017Results posted

A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids

A Phase 2 interventional study of Belatacept and Cyclosporine A in Renal Transplant, sponsored by Bristol-Myers Squibb. Completed at 44 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-05.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn if conversion to belatacept from cyclosporine or tacrolimus will preserve kidney function in people who have had a kidney transplant. The safety and tolerability of this treatment will also be studied

02

Conditions studied

  • Renal Transplant
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Men and women age 18 and older
  • 6-36 months after kidney transplant receiving cyclosporine or tacrolimus
  • calculated ≥35 and ≤75mL/min/1.73 m²
  • subjects must have completed 1 year in the IM103-010ST and remained on study treatment (Long Term Extension)

Key Exclusion Criteria:

  • Significant infection
  • acute rejection within 3 months
  • prior graft loss due to rejection
  • pregnancy
  • positive crossmatch
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    A: Belatacept

    Drug: Belatacept

  • Active comparator
    B: calcineurin inhibitor (CNI)-based immunosuppressive regimen

    Drug: Cyclosporine A · Drug: Tacrolimus

Interventions

  • IV, IV Infusion, 5 mg/kg once every 28 days for one year

    Also known as: BMS-224818

  • Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year

  • Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 12 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)

    Calculated GFR assessment used the modification of diet in renal disease (MDRD) formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Baseline = value at screening. Randomization/First Dose was on Day 1.

    Time frame: Baseline to 12 months post randomization

Secondary outcomes

  1. Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 6 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)

    Calculated GFR assessment used the modification of diet in renal disease (MDRD) formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Baseline = value at screening.

    Time frame: Baseline to 6 months post randomization

  2. Number of Participants With Acute Rejection (AR) by Months 6 and 12 Post Randomization - All Randomized Participants

    AR defined: if either a or b was satisfied: a: the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy proven AR (AR of Banff histopathologic classification Grade IA or higher as assessed by the blinded central pathologist); b: the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy proven AR, and the participant was treated for this episode. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. AR is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection.

    Time frame: At 6 and 12 months post randomization

  3. Percentage of Participants Surviving With a Functioning Graft, Have Graft Loss or Death (Graft Loss, Death, Death With Functioning Graft) By Month 6 and Month 12 Post Randomization

    Graft loss was defined as either functional loss or physical loss. Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL (530 μmol/L) for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that the participant undergoes re-transplantation.

    Time frame: At 6 and 12 months post randomization

  4. Number of Participants Who Had Any Study Drug Dose Alteration by Month 12 Due to Any Reason - Randomized and Treated Participants

    Reasons for study drug dose modification included categories of decline in renal function (as determined by the investigator), treatment of acute rejection, and other reasons. More than 1 reason could be given for dose alteration.

    Time frame: Month 12

  5. Percentage of Participants With a Composite Endpoint of Death, Graft Loss and Acute Rejection at Month 12

    Percentage=number with composite divided by number randomized. Graft loss was functional loss or physical loss. Functional loss = sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that participant undergoes re-transplantation. AR: if either a or b: (a) the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy-proven AR (grade IA or higher as assessed by the blinded central pathologist); (b) the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy-proven AR, and the participant was treated for it.

    Time frame: 12 Months post randomization

  6. Percentage of Participants With New Onset Diabetes Mellitus - All Randomized Participants

    A participant who did not have diabetes prior to randomization is determined to have new onset diabetes mellitus if they received an antidiabetic medication for a duration of at least 30 days or at least two fasting plasma glucose (FPG) tests indicated that FPG is \>=126 mg/dL. Percentage was the number of participants with new onset of diabetes mellitus divided by the number of participants without pre-randomization diabetes.

    Time frame: Month 12 post randomization

  7. Number of Participants With Anti-Donor Human Leukocyte Antigen (HLA) Positive Antibodies

    Samples were obtained at Day 1 (first dose), Week 24, and Week 52 (or end of therapy). This was a cumulative summary in that once a participant was positive, that participant remained positive for later time points. Evaluation of anti-donor HLA antibodies was performed by an external laboratory (Emory University, Atlanta, Georgia).

    Time frame: Month 6 and Month 12 Post Randomization

  8. Mean Change From Baseline to Month 6 and to Month 12 in Serum Creatinine - All Randomized Participants

    Baseline was value at screening or prior to first dose of study drug. Serum creatinine was measured in milligrams per deciliter (mg/dL). Baseline = value at screening.

    Time frame: Baseline to Month 6 and Month 12 Post Randomization

  9. Number of Participants With Serious Adverse Events (SAEs), Deaths, and Discontinuation Due to Adverse Events (AEs) From First Dose up to Month 12

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

    Time frame: First Dose (Day 1) to Month 12

  10. Mean Change From Baseline in SF-36 Questionnaire Physical Component Score and in Mental Component Score at Month 12 - All Randomized Participants

    SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire. The subscale in the mental component (MCS) part of the instrument ranged from 1 to 6 with 1=all of the time and 6= none of the time. The subscale for physical component (PCS) ranged from 1 to 3 with 1=Yes, limited a lot and 3=No, not limited at all. The subscale for the extent that physical health or emotional problems interfered with normal activities ranged from 1 to 5 with 1=not at all and 5= extremely. Baseline was at randomization or prior to first dose. Baseline = value at screening. The subscale scores were transformed using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life.

    Time frame: Baseline, Month 12

  11. Mean Change From Baseline to Month 12 for Eight Domain Scores of Quality of Life (QoL) Instrument SF-36 - All Randomized Participants

    SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 8 domains of physical and mental component summaries: physical function, role limitations due to physical problems, pain, general health perception, and vitality, social function, role limitations due to emotional problems, and mental health. All domains were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life.

    Time frame: Baseline (screening) to Month 12

  12. Ridit Score at Month 12 - All Randomized Participants

    The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) was used to assess the occurrence (never, occasionally, regularly, almost always, always) and distress (0=no distress to 4=terrible distress) of symptoms associated with immunosuppressive therapies. Ridit (relative to an identified distribution) analysis (Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley \& Sons, Inc. 1991) was used. Ridit scores were calculated at 12 months for overall symptom occurrence score and overall symptom distress. The Ridit score reflects the probability that a score observed for an individual randomly selected from a group would be higher (worse symptom) than a score observed for a randomly selected individual from the reference group. The reference group was constituted by the frequency distribution of the responses of all participants on all items at baseline. The ridit of the reference group is by definition, 0.5.

    Time frame: Month 12

  13. Number of Participants Meeting Marked Laboratory Abnormality Criteria From Baseline up to Month 12 - Randomized and Treated Participants

    Upper limits of normal (ULL). Leukocytes: \< 2.0\*10\^3 cells per microliter (c/µL); Lymphocytes (absolute): \< 0.5\*10\^3 c/µL; bilirubin: \> 3.0\*ULN milligrams per deciliter (mg/dL); Potassium: \< 3.0 milliequivalents per liter (meq/L) or \> 6.0 meq/L; Magnesium \>2.6 meq/L; Sodium: \< 130 meq/L; Phosphorus: \< 2.0 mg/dL; Uric Acid: \> 10 mg/dL. Baseline = value at screening.

    Time frame: Baseline up to Month 12

  14. Long Term Period: Mean Change From Baseline to 54 Months Post Randomization in Calculated GFR on Imputed Values at Specified Timepoints - Intent to Treat (ITT) Participants Who Entered LT Period

    ITT=participants randomized to their original treatment arm and who entered the LT period are presented. Baseline=value at screening. Calculated GFR assessment used the MDRD formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value of 0 was imputed and carried forward after death or graft loss up to the end of the analysis period. Sponsor discontinued the CNI treatment arm in Year 3, and participants treated with CNI could elect to switch to belatacept. If a participant did not switch to belatacept, they were required to discontinue from the study. Therefore, efficacy results from Month 36 through Month 54 are difficult to interpret. No formal comparisons were planned between the belatacept and CNI treatment groups post Month 36, and the data up to the final database lock should be interpreted with caution.

    Time frame: Baseline, Month 3, 6, 12, 18, 24, 30, 36, 42, 48, 54

  15. Long Term Period: Number of Participants With Acute Rejection (AR) - All Randomized Participants in LT Period

    AR was defined: if either a or b was satisfied: (a) the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy proven AR (AR of Banff histopathologic classification grade IA or higher as assessed by the blinded central pathologist); (b) the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy proven AR, and the participant was treated for this episode. Banff 97 working classification of kidney transplant pathology was used to categorize the severity of the AR.

    Time frame: Post Month 12 up to Year 6 of the Study

  16. Long Term Period: Number of Participants Who Survived With a Functioning Graft or Survived With Pure Graft Loss or Death With Functioning Graft - ITT Participants Who Entered the LT Period

    Graft loss = either pure graft loss (participant survived to the end of the study period after graft loss) or death with functioning graft. Pure graft loss = either functional loss or physical loss. Functional loss = a sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL (530 μmol/L) for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that the participant undergoes re-transplantation. The table was designed with built-in redundancy to capture all possible combinations of death and/or graft loss, but not all lines can be summed to reach the total number surviving and the total number who die and/or lose grafts. If a participant experiences pure graft loss and dies at a later date independent of the graft loss event, they are counted only once in the cumulative tabulation of death or graft loss. Only the first event experienced by the participant counted toward the cumulative total.

    Time frame: Post Months 24, 36, 48, up to Year 6 of the Study

  17. Long Term Period: Percentage of Participants With New Onset Diabetes Mellitus Up to Month 36- All Randomized Participants Who Entered LT Period

    A participant who did not have diabetes prior to randomization is determined to have new onset diabetes mellitus if they received an antidiabetic medication for a duration of at least 30 days or at least two fasting plasma glucose (FPG) tests indicated that FPG is \>=126 mg/dL. Percentage was the number of participants with new onset of diabetes mellitus divided by the number of participants without pre-randomization diabetes.

    Time frame: Baseline (screening) up to Month 36 post randomization

  18. Long Term Period: Number of Participants With SAEs, Death, Discontinuation Due to AEs - All Randomized Participants Who Entered the Long Term Period

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

    Time frame: First dose after randomization (Day 1) to 56 days post last dose, up to Year 6 of the Study

  19. Long Term Period: Number of Participants With AEs of Special Interest - All Randomized Participants Who Entered the Long Term Period

    Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Serious Infections, Thrombolic/embolic events, Autoimmune Disease, Malignancy, Peri-infusional reactions (only belatacept treatment group was IV) , Acute Peri-infusional events occurring within 24 hours of injection, Pulmonary Edema and Congestive Heart Failure. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: First dose after randomization (Day 1) to last dose, plus 56 days, up to Year 6 of the Study

  20. Long Term Period: Mean Change From Baseline to Month 54 in Serum Creatinine- ITT Participants Who Entered LT Period

    Baseline was value at screening. Serum creatinine was measured in mg/dL. Only participants who entered into Long Term Period were included in the analysis.

    Time frame: Baseline, Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54

  21. Long Term Period: Number of Participants Meeting Marked Laboratory Abnormality Criteria - All ITT Participants Who Entered the Long Term Period

    Upper limits of normal (ULN). Hemoglobin: \< 8 g/dL; Platelet count: \< 50\*10\^9 c/L; Leukocytes: \< 2.0\*10\^3 c/µL; Lymphocytes (absolute): \< 0.5\*10\^3 c/µL; Neutrophils: \< 1.0\*10\^3 c/µL; Alanine Aminotransferase (ALT): \> 5.0\*ULN Units per liter (U/L); bilirubin: \> 3.0\*ULN mg/dL; Creatinine: \> 3.0\*ULN mg/dL; Calcium: \< 7 mg/dL; Bicarbonate: \> 12.5 mg/dL; Potassium: \< 3.0 meq/L or \> 6.0 meq/L; Magnesium \>2.6 meq/L; Sodium: \< 130 meq/L; Phosphorus: \< 2.0 mg/dL; Uric Acid: \> 10 mg/dL.

    Time frame: Baseline (Screening), up to Year 6 of the Study

  22. Long Term Period: Mean Change From Baseline to Month 54 in Systolic Blood Pressure

    Blood pressure was measured while the participant was sitting quietly for 5 minutes and was measured in millimeters of mercury (mmHg). Baseline was value at screening. Only those participants who entered long term period were evaluated.

    Time frame: Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54

  23. Long Term Period: Mean Change From Baseline to Month 54 in Diastolic Blood Pressure

    Blood pressure was measured while the participant was sitting quietly for 5 minutes and was measured in mmHg. Baseline was value at screening. Only those participants who entered long term period were evaluated.

    Time frame: Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54

  24. Participants Who Switched From CNI to Belatacept in Long Term Period : Mean Change in Calculated GFR Based on Imputed Values From Day of Switch to Week 96 Post Switch

    Calculated GFR assessment used the MDRD formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Day of Switch = the first belatacept infusion day.

    Time frame: Day of Switch (first belatacept dose) to Week 96 Post Switch

  25. Participants Who Switched to Belatacept in Long Term Period: Number of Participants With AEs and SAEs

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Day of Switch = the first belatacept infusion day.

    Time frame: Day of Switch (first dose of belatacept ) to last dose plus 56 days, up to Year 6 of the Study

07

Results

Posted Jan 5, 2017
Limitations and caveats
CNI arm discontinued Year 3, and those not switching treatment discontinued from study. No formal comparisons in calculated GFR were planned post Month 36, and these data up to the final database lock should be interpreted with caution.

Participant flow

Randomized
Participant flow — Randomized
MilestoneBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Started8489
Completed8388
Not completed11
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject01
Treatment (up to 12 Months)
Participant flow — Treatment (up to 12 Months)
MilestoneBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Started8388
Completed8186
Not completed22
Withdrew: Death01
Withdrew: Lack of efficacy20
Withdrew: Non-specified01
Long Term (LT)
Participant flow — Long Term (LT)
MilestoneBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Started8181
Completed7064
Not completed1117
Withdrew: Adverse event15
Withdrew: Withdrawal by subject47
Withdrew: Pregnancy01
Withdrew: Lost to follow-up10
Withdrew: Death40
Withdrew: Lack of efficacy02
Withdrew: Non-specified12
Switched From CNI to Belatacept in LT
Participant flow — Switched From CNI to Belatacept in LT
MilestoneBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Started380
Completed320
Not completed60
Withdrew: Withdrawal by subject20
Withdrew: Adverse event40

Outcome measures

SecondaryMean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 6 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)

Calculated GFR assessment used the modification of diet in renal disease (MDRD) formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Baseline = value at screening.

Time frame:
Baseline to 6 months post randomization
Reported as:
Mean · mL/min/1.73 m^2
Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 6 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)
mL/min/1.73 m^2Belatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 6 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)6.9 ± 11.971.1 ± 9.84
SecondaryNumber of Participants With Acute Rejection (AR) by Months 6 and 12 Post Randomization - All Randomized Participants

AR defined: if either a or b was satisfied: a: the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy proven AR (AR of Banff histopathologic classification Grade IA or higher as assessed by the blinded central pathologist); b: the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy proven AR, and the participant was treated for this episode. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. AR is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection.

Time frame:
At 6 and 12 months post randomization
Reported as:
Number · participants
Number of Participants With Acute Rejection (AR) by Months 6 and 12 Post Randomization - All Randomized Participants
participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Total Number by Month 660
By Month 6 Mild Acute (IA)10
Month 6 Mild Acute (IB)10
Month 6 Moderate Acute (IIA)30
Month 6 Moderate Acute (IIB)10
Month 6 Severe Acute (III)00
Total Number by Month 1260
Month 12 Mild Acute (IA)10
Month 12 Mild Acute (IB)10
Month12 Moderate Acute (IIA)30
Month 12 Moderate Acute (IIB)10
Month 12 Severe Acute (III)00
Statistical analysis
  • Belatacept 5 mg/kg vs Calcineurin Inhibitor (CNI) · Difference in percentage: 7.1 · 95% CI 2.1 to 14.9
  • Belatacept 5 mg/kg vs Calcineurin Inhibitor (CNI) · Difference in percentage: 7.1 · 95% CI 2.1 to 14.9
SecondaryPercentage of Participants Surviving With a Functioning Graft, Have Graft Loss or Death (Graft Loss, Death, Death With Functioning Graft) By Month 6 and Month 12 Post Randomization

Graft loss was defined as either functional loss or physical loss. Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL (530 μmol/L) for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that the participant undergoes re-transplantation.

Time frame:
At 6 and 12 months post randomization
Reported as:
Number · percentage of participants
Percentage of Participants Surviving With a Functioning Graft, Have Graft Loss or Death (Graft Loss, Death, Death With Functioning Graft) By Month 6 and Month 12 Post Randomization
percentage of participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Month 6 Surviving with Functioning Graft100.098.9
Month 6 Graft Loss or Death0.01.1
Month 6 Graft Loss0.00.0
Month 6 Death0.01.1
Month 6 Death with Functioning Graft0.01.1
Month 12 Surviving with Functioning Graft100.098.9
Month 12 Graft Loss or Death0.01.1
Month 12 Graft Loss0.00.0
Month 12 Death0.01.1
Month 12 Death with Functioning Graft0.01.1
Statistical analysis
  • Belatacept 5 mg/kg vs Calcineurin Inhibitor (CNI) · Percent difference: 1.1 · 95% CI -3.3 to 6.1
  • Belatacept 5 mg/kg vs Calcineurin Inhibitor (CNI) · Percent difference: 1.1 · 95% CI -3.3 to 6.1
SecondaryNumber of Participants Who Had Any Study Drug Dose Alteration by Month 12 Due to Any Reason - Randomized and Treated Participants

Reasons for study drug dose modification included categories of decline in renal function (as determined by the investigator), treatment of acute rejection, and other reasons. More than 1 reason could be given for dose alteration.

Time frame:
Month 12
Reported as:
Number · participants
Number of Participants Who Had Any Study Drug Dose Alteration by Month 12 Due to Any Reason - Randomized and Treated Participants
participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Number with Dose Alteration (Any Reason)1562
Decline in renal function04
Treatment of Acute Rejection00
Other1561
PrimaryMean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 12 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)

Calculated GFR assessment used the modification of diet in renal disease (MDRD) formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Baseline = value at screening. Randomization/First Dose was on Day 1.

Time frame:
Baseline to 12 months post randomization
Reported as:
Mean · mL/min/1.73 m^2
Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 12 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)
mL/min/1.73 m^2Belatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 12 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)7.0 ± 11.992.1 ± 10.34
SecondaryPercentage of Participants With a Composite Endpoint of Death, Graft Loss and Acute Rejection at Month 12

Percentage=number with composite divided by number randomized. Graft loss was functional loss or physical loss. Functional loss = sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that participant undergoes re-transplantation. AR: if either a or b: (a) the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy-proven AR (grade IA or higher as assessed by the blinded central pathologist); (b) the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy-proven AR, and the participant was treated for it.

Time frame:
12 Months post randomization
Reported as:
Number · percentage of participants
Percentage of Participants With a Composite Endpoint of Death, Graft Loss and Acute Rejection at Month 12
percentage of participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Percentage of Participants With a Composite Endpoint of Death, Graft Loss and Acute Rejection at Month 127.1 (1.6 to 12.7)1.1 (0.0 to 6.1)
Statistical analysis
  • Belatacept 5 mg/kg vs Calcineurin Inhibitor (CNI) · Difference: 6.0 · 95% CI -0.1 to 13.8
SecondaryPercentage of Participants With New Onset Diabetes Mellitus - All Randomized Participants

A participant who did not have diabetes prior to randomization is determined to have new onset diabetes mellitus if they received an antidiabetic medication for a duration of at least 30 days or at least two fasting plasma glucose (FPG) tests indicated that FPG is \>=126 mg/dL. Percentage was the number of participants with new onset of diabetes mellitus divided by the number of participants without pre-randomization diabetes.

Time frame:
Month 12 post randomization
Reported as:
Number · percentage of participants
Percentage of Participants With New Onset Diabetes Mellitus - All Randomized Participants
percentage of participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Percentage of Participants With New Onset Diabetes Mellitus - All Randomized Participants1.7 (0.0 to 9.1)2.9 (0.4 to 10.2)
SecondaryNumber of Participants With Anti-Donor Human Leukocyte Antigen (HLA) Positive Antibodies

Samples were obtained at Day 1 (first dose), Week 24, and Week 52 (or end of therapy). This was a cumulative summary in that once a participant was positive, that participant remained positive for later time points. Evaluation of anti-donor HLA antibodies was performed by an external laboratory (Emory University, Atlanta, Georgia).

Time frame:
Month 6 and Month 12 Post Randomization
Reported as:
Number · participants
Number of Participants With Anti-Donor Human Leukocyte Antigen (HLA) Positive Antibodies
participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Baseline (n=80,82)33
Month 6 (n=82,8234
Month 12 (n=82, 83)34
SecondaryMean Change From Baseline to Month 6 and to Month 12 in Serum Creatinine - All Randomized Participants

Baseline was value at screening or prior to first dose of study drug. Serum creatinine was measured in milligrams per deciliter (mg/dL). Baseline = value at screening.

Time frame:
Baseline to Month 6 and Month 12 Post Randomization
Reported as:
Mean · mg/dL
Mean Change From Baseline to Month 6 and to Month 12 in Serum Creatinine - All Randomized Participants
mg/dLBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Month 6 (n=81,82)-0.1 ± 0.26-0.0 ± 0.20
Month 12 (n=81,86)-0.1 ± 0.28-0.0 ± 0.21
SecondaryNumber of Participants With Serious Adverse Events (SAEs), Deaths, and Discontinuation Due to Adverse Events (AEs) From First Dose up to Month 12

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Time frame:
First Dose (Day 1) to Month 12
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs), Deaths, and Discontinuation Due to Adverse Events (AEs) From First Dose up to Month 12
participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Deaths01
SAEs2017
Treatment Related SAEs94
Discontinued due to SAEs10
Treatment Related AEs2427
Discontinued due to AEs10
SecondaryMean Change From Baseline in SF-36 Questionnaire Physical Component Score and in Mental Component Score at Month 12 - All Randomized Participants

SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire. The subscale in the mental component (MCS) part of the instrument ranged from 1 to 6 with 1=all of the time and 6= none of the time. The subscale for physical component (PCS) ranged from 1 to 3 with 1=Yes, limited a lot and 3=No, not limited at all. The subscale for the extent that physical health or emotional problems interfered with normal activities ranged from 1 to 5 with 1=not at all and 5= extremely. Baseline was at randomization or prior to first dose. Baseline = value at screening. The subscale scores were transformed using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life.

Time frame:
Baseline, Month 12
Reported as:
Mean · units on a scale
Mean Change From Baseline in SF-36 Questionnaire Physical Component Score and in Mental Component Score at Month 12 - All Randomized Participants
units on a scaleBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
MCS (n=64, 75)0.3 ± 1.032-0.7 ± 0.959
PCS (n=64, 75)0.5 ± 0.8080.8 ± 0.752
Statistical analysis
  • Belatacept 5 mg/kg vs Calcineurin Inhibitor (CNI) · ANCOVA · p = 0.4491 · Mean difference (net): 1.1 · 95% CI -1.7 to 3.9
  • Belatacept 5 mg/kg vs Calcineurin Inhibitor (CNI) · ANCOVA · p = 0.7892 · Mean difference (net): -0.3 · 95% CI -2.5 to 1.9
SecondaryMean Change From Baseline to Month 12 for Eight Domain Scores of Quality of Life (QoL) Instrument SF-36 - All Randomized Participants

SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 8 domains of physical and mental component summaries: physical function, role limitations due to physical problems, pain, general health perception, and vitality, social function, role limitations due to emotional problems, and mental health. All domains were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life.

Time frame:
Baseline (screening) to Month 12
Reported as:
Mean · units on a scale
Mean Change From Baseline to Month 12 for Eight Domain Scores of Quality of Life (QoL) Instrument SF-36 - All Randomized Participants
units on a scaleBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Bodily Pain (n=74,79)0.7 ± 0.9790.3 ± 0.950
General Health (n=75,79)1.6 ± 0.9210.9 ± 0.900
Mental Health (n=73,79)0.7 ± 0.913-0.1 ± 0.881
Physical Functioning (n=67,75)-0.5 ± 0.8400.8 ± 0.800
Role Emotional (n=75,79)-1.4 ± 1.043-0.4 ± 1.021
Role Physical (n=75,79)0.5 ± 0.9610.2 ± 0.939
Social Functioning (n=75,79)0.9 ± 0.929-0.5 ± 0.906
Vitality (n=73,79)0.2 ± 0.973-0.2 ± 0.940
SecondaryRidit Score at Month 12 - All Randomized Participants

The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) was used to assess the occurrence (never, occasionally, regularly, almost always, always) and distress (0=no distress to 4=terrible distress) of symptoms associated with immunosuppressive therapies. Ridit (relative to an identified distribution) analysis (Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley \& Sons, Inc. 1991) was used. Ridit scores were calculated at 12 months for overall symptom occurrence score and overall symptom distress. The Ridit score reflects the probability that a score observed for an individual randomly selected from a group would be higher (worse symptom) than a score observed for a randomly selected individual from the reference group. The reference group was constituted by the frequency distribution of the responses of all participants on all items at baseline. The ridit of the reference group is by definition, 0.5.

Time frame:
Month 12
Reported as:
Number · Ridit score
Ridit Score at Month 12 - All Randomized Participants
Ridit scoreBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Symptom Distress (n=46,44)0.51620.5014
Symptom Occurrence (n=46,45)0.50740.4998
Statistical analysis
  • Belatacept 5 mg/kg vs Calcineurin Inhibitor (CNI) · Estimated difference: .0076 · 95% CI -.010 to .0252
  • Belatacept 5 mg/kg vs Calcineurin Inhibitor (CNI) · Estimated difference: .0148 · 95% CI -.002 to .0321
SecondaryNumber of Participants Meeting Marked Laboratory Abnormality Criteria From Baseline up to Month 12 - Randomized and Treated Participants

Upper limits of normal (ULL). Leukocytes: \< 2.0\*10\^3 cells per microliter (c/µL); Lymphocytes (absolute): \< 0.5\*10\^3 c/µL; bilirubin: \> 3.0\*ULN milligrams per deciliter (mg/dL); Potassium: \< 3.0 milliequivalents per liter (meq/L) or \> 6.0 meq/L; Magnesium \>2.6 meq/L; Sodium: \< 130 meq/L; Phosphorus: \< 2.0 mg/dL; Uric Acid: \> 10 mg/dL. Baseline = value at screening.

Time frame:
Baseline up to Month 12
Reported as:
Number · participants
Number of Participants Meeting Marked Laboratory Abnormality Criteria From Baseline up to Month 12 - Randomized and Treated Participants
participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Leukocytes Low01
Lymphocytes Low40
Bilirubin High01
Potassium Low11
Potassium High10
Magnesium High51
Sodium Low11
Phosphorus Inorganic Low52
Uric Acid High46
SecondaryLong Term Period: Mean Change From Baseline to 54 Months Post Randomization in Calculated GFR on Imputed Values at Specified Timepoints - Intent to Treat (ITT) Participants Who Entered LT Period

ITT=participants randomized to their original treatment arm and who entered the LT period are presented. Baseline=value at screening. Calculated GFR assessment used the MDRD formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value of 0 was imputed and carried forward after death or graft loss up to the end of the analysis period. Sponsor discontinued the CNI treatment arm in Year 3, and participants treated with CNI could elect to switch to belatacept. If a participant did not switch to belatacept, they were required to discontinue from the study. Therefore, efficacy results from Month 36 through Month 54 are difficult to interpret. No formal comparisons were planned between the belatacept and CNI treatment groups post Month 36, and the data up to the final database lock should be interpreted with caution.

Time frame:
Baseline, Month 3, 6, 12, 18, 24, 30, 36, 42, 48, 54
Reported as:
Mean · mL/min/1.73 m^2
Long Term Period: Mean Change From Baseline to 54 Months Post Randomization in Calculated GFR on Imputed Values at Specified Timepoints - Intent to Treat (ITT) Participants Who Entered LT Period
mL/min/1.73 m^2Belatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Month 3 (n=81, 81)5.1 ± 10.160.4 ± 9.92
Month 6 (n=80, 77)7.1 ± 11.942.3 ± 8.95
Month 12 (n=81, 81)7.1 ± 12.022.8 ± 9.70
Month 18 (n=81, 75)8.8 ± 13.880.1 ± 12.47
Month 24 (n=81, 78)8.8 ± 13.77-0.0 ± 14.84
Month 30 (n=80, 69)9.1 ± 16.100.1 ± 14.45
Month 36 (n=57, 52)7.7 ± 15.913.9 ± 17.46
Month 42 (n=71, 54)9.1 ± 17.560.6 ± 17.04
Month 48 (n=16, 32)-1.7 ± 32.154.2 ± 18.03
Month 54 (n=14, 26)-0.9 ± 35.692.4 ± 18.72
SecondaryLong Term Period: Number of Participants With Acute Rejection (AR) - All Randomized Participants in LT Period

AR was defined: if either a or b was satisfied: (a) the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy proven AR (AR of Banff histopathologic classification grade IA or higher as assessed by the blinded central pathologist); (b) the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy proven AR, and the participant was treated for this episode. Banff 97 working classification of kidney transplant pathology was used to categorize the severity of the AR.

Time frame:
Post Month 12 up to Year 6 of the Study
Reported as:
Number · participants
Long Term Period: Number of Participants With Acute Rejection (AR) - All Randomized Participants in LT Period
participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Total Number54
Mild Acute IA00
Mild Acute IB11
Moderate Acute IIA32
Moderate Acute IIB11
Severe Acute III00
SecondaryLong Term Period: Number of Participants Who Survived With a Functioning Graft or Survived With Pure Graft Loss or Death With Functioning Graft - ITT Participants Who Entered the LT Period

Graft loss = either pure graft loss (participant survived to the end of the study period after graft loss) or death with functioning graft. Pure graft loss = either functional loss or physical loss. Functional loss = a sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL (530 μmol/L) for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that the participant undergoes re-transplantation. The table was designed with built-in redundancy to capture all possible combinations of death and/or graft loss, but not all lines can be summed to reach the total number surviving and the total number who die and/or lose grafts. If a participant experiences pure graft loss and dies at a later date independent of the graft loss event, they are counted only once in the cumulative tabulation of death or graft loss. Only the first event experienced by the participant counted toward the cumulative total.

Time frame:
Post Months 24, 36, 48, up to Year 6 of the Study
Reported as:
Number · participants
Long Term Period: Number of Participants Who Survived With a Functioning Graft or Survived With Pure Graft Loss or Death With Functioning Graft - ITT Participants Who Entered the LT Period
participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Month 24 Surviving with Functioning Graft8080
Month 24 Graft Loss or Death11
Month 24 Graft Loss11
Month 24 Death00
Month 36 Surviving with Functioning Graft7980
Month 36 Graft Loss or Death21
Month 36 Graft Loss11
Month 36 Death10
Month 36 Death with Functioning Graft10
Month 48 Surviving with Functioning Graft7880
Month 48 Graft Loss or Death31
Month 48 Graft Loss11
Month 48 Death20
Month 48 Death with Functioning Graft20
up to year 6 Surviving with Functioning Graft7680
up to year 6 Graft Loss or Death51
up to year 6 Graft Loss11
up to year 6, Death40
up to year 6 Death with Functioning Graft40
SecondaryLong Term Period: Percentage of Participants With New Onset Diabetes Mellitus Up to Month 36- All Randomized Participants Who Entered LT Period

A participant who did not have diabetes prior to randomization is determined to have new onset diabetes mellitus if they received an antidiabetic medication for a duration of at least 30 days or at least two fasting plasma glucose (FPG) tests indicated that FPG is \>=126 mg/dL. Percentage was the number of participants with new onset of diabetes mellitus divided by the number of participants without pre-randomization diabetes.

Time frame:
Baseline (screening) up to Month 36 post randomization
Reported as:
Number · percentage of participants
Long Term Period: Percentage of Participants With New Onset Diabetes Mellitus Up to Month 36- All Randomized Participants Who Entered LT Period
percentage of participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Long Term Period: Percentage of Participants With New Onset Diabetes Mellitus Up to Month 36- All Randomized Participants Who Entered LT Period6.9 (1.9 to 16.7)4.8 (1.0 to 13.5)
SecondaryLong Term Period: Number of Participants With SAEs, Death, Discontinuation Due to AEs - All Randomized Participants Who Entered the Long Term Period

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Time frame:
First dose after randomization (Day 1) to 56 days post last dose, up to Year 6 of the Study
Reported as:
Number · participants
Long Term Period: Number of Participants With SAEs, Death, Discontinuation Due to AEs - All Randomized Participants Who Entered the Long Term Period
participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Deaths40
SAEs4540
Treatment Related SAEs1814
Discontinued Due to SAEs12
Treatment Related AEs3843
Discontinued Due to AEs13
SecondaryLong Term Period: Number of Participants With AEs of Special Interest - All Randomized Participants Who Entered the Long Term Period

Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Serious Infections, Thrombolic/embolic events, Autoimmune Disease, Malignancy, Peri-infusional reactions (only belatacept treatment group was IV) , Acute Peri-infusional events occurring within 24 hours of injection, Pulmonary Edema and Congestive Heart Failure. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
First dose after randomization (Day 1) to last dose, plus 56 days, up to Year 6 of the Study
Reported as:
Number · participants
Long Term Period: Number of Participants With AEs of Special Interest - All Randomized Participants Who Entered the Long Term Period
participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Malignancies89
Serious Infections2626
Thrombolic/embolic30
Peri-infusional Events370
Acute Peri-infusional Events50
Autoimmune Disease21
Pulmonary Edema/Congestive Heart Failure32
SecondaryLong Term Period: Mean Change From Baseline to Month 54 in Serum Creatinine- ITT Participants Who Entered LT Period

Baseline was value at screening. Serum creatinine was measured in mg/dL. Only participants who entered into Long Term Period were included in the analysis.

Time frame:
Baseline, Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54
Reported as:
Mean · mg/dL
Long Term Period: Mean Change From Baseline to Month 54 in Serum Creatinine- ITT Participants Who Entered LT Period
mg/dLBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Month 3 (n=81,81)-0.1 ± 0.240.0 ± 0.21
Month 6 (n=81,77)-0.1 ± 0.26-0.0 ± 0.19
Month 12 (n=81,81)-0.1 ± 0.28-0.0 ± 0.21
Month 18 (n=80,75)-0.1 ± 0.310.1 ± 0.77
Month 24 (n=80,77)-0.1 ± 0.280.0 ± 0.37
Month 30 (n=78, 68)-0.2 ± 0.350.0 ± 0.32
Month 36 (n=55, 51)-0.1 ± 0.29-0.0 ± 0.39
Month 42 (n=68, 53)-0.2 ± 0.300.0 ± 0.41
Month 48 (n=12, 31)-0.2 ± 0.16-0.1 ± 0.30
Month 54 (n=10, 25)-0.3 ± 0.25-0.1 ± 0.29
SecondaryLong Term Period: Number of Participants Meeting Marked Laboratory Abnormality Criteria - All ITT Participants Who Entered the Long Term Period

Upper limits of normal (ULN). Hemoglobin: \< 8 g/dL; Platelet count: \< 50\*10\^9 c/L; Leukocytes: \< 2.0\*10\^3 c/µL; Lymphocytes (absolute): \< 0.5\*10\^3 c/µL; Neutrophils: \< 1.0\*10\^3 c/µL; Alanine Aminotransferase (ALT): \> 5.0\*ULN Units per liter (U/L); bilirubin: \> 3.0\*ULN mg/dL; Creatinine: \> 3.0\*ULN mg/dL; Calcium: \< 7 mg/dL; Bicarbonate: \> 12.5 mg/dL; Potassium: \< 3.0 meq/L or \> 6.0 meq/L; Magnesium \>2.6 meq/L; Sodium: \< 130 meq/L; Phosphorus: \< 2.0 mg/dL; Uric Acid: \> 10 mg/dL.

Time frame:
Baseline (Screening), up to Year 6 of the Study
Reported as:
Number · participants
Long Term Period: Number of Participants Meeting Marked Laboratory Abnormality Criteria - All ITT Participants Who Entered the Long Term Period
participantsBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Hemoglobin Low10
Platelet Count Low11
Leukocytes Low01
Lymphocytes Low55
Neutrophils Low12
ALT High01
Bilirubin High01
Creatinine High01
Calcium Low02
Bicarbonate Low01
Potassium Low21
Potassium High13
Magnesium High61
Sodium Low21
Phosphorus Inorganic Low73
Uric Acid High77
SecondaryLong Term Period: Mean Change From Baseline to Month 54 in Systolic Blood Pressure

Blood pressure was measured while the participant was sitting quietly for 5 minutes and was measured in millimeters of mercury (mmHg). Baseline was value at screening. Only those participants who entered long term period were evaluated.

Time frame:
Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54
Reported as:
Mean · mmHg
Long Term Period: Mean Change From Baseline to Month 54 in Systolic Blood Pressure
mmHgBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Month 6 (n=78,73)-3.6 ± 19.06-0.4 ± 17.52
Month 12 (n=77,71)-4.6 ± 18.33-4.2 ± 16.26
Month 18 (n=77,1)-4.4 ± 17.409.0 ± NA
Month 24 (n=77,1)-6.0 ± 17.944.0 ± NA
Month 30 (n=75, 6)-3.6 ± 17.94-0.5 ± 20.78
Month 36 (n=75,13)-6.6 ± 17.491.2 ± 13.61
Month 42 (n=74, 29)-5.4 ± 17.08-3.5 ± 19.33
Month 48 (n=73,32)-4.4 ± 16.16-3.7 ± 14.35
Month 54 (n=72,33)-4.9 ± 16.90-3.8 ± 12.96
SecondaryLong Term Period: Mean Change From Baseline to Month 54 in Diastolic Blood Pressure

Blood pressure was measured while the participant was sitting quietly for 5 minutes and was measured in mmHg. Baseline was value at screening. Only those participants who entered long term period were evaluated.

Time frame:
Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54
Reported as:
Mean · mmHg
Long Term Period: Mean Change From Baseline to Month 54 in Diastolic Blood Pressure
mmHgBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)
Month 6 (n=78,73)-2.0 ± 10.78-2.2 ± 10.50
Month 12 (n=77,71)-2.5 ± 11.54-1.0 ± 11.04
Month 18 (n=77,1)-1.7 ± 11.7910.0 ± NA
Month 24 (n=77,1)-3.9 ± 10.1913.0 ± NA
Month 30 (n=75,6)-1.8 ± 10.975.7 ± 9.14
Month 36 (n=75,13)-1.9 ± 10.86-1.6 ± 7.69
Month 42 (n=74,29)-1.7 ± 11.70-3.8 ± 10.99
Month 48 (n=73, 32)-3.2 ± 10.53-3.6 ± 11.92
Month 54 (n=72, 33)-1.1 ± 10.86-3.6 ± 11.72
SecondaryParticipants Who Switched From CNI to Belatacept in Long Term Period : Mean Change in Calculated GFR Based on Imputed Values From Day of Switch to Week 96 Post Switch

Calculated GFR assessment used the MDRD formula. GFR was measured as mL/min/1.73 m\^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Day of Switch = the first belatacept infusion day.

Time frame:
Day of Switch (first belatacept dose) to Week 96 Post Switch
Reported as:
Mean · mL/min/1.73 m^2
Participants Who Switched From CNI to Belatacept in Long Term Period : Mean Change in Calculated GFR Based on Imputed Values From Day of Switch to Week 96 Post Switch
mL/min/1.73 m^2Belatacept 5 mg/kg in Participants Switched During LT Period
Week 4 Post Switch (n=30)1.3 ± 5.85
Week 12 Post Switch (n=33)3.3 ± 9.88
Week 24 Post Switch (n= 29)2.1 ± 10.66
Week 48 Post Switch (n= 12)0.3 ± 7.75
Week 96 Post Switch (n= 8)0.1 ± 10.33
SecondaryParticipants Who Switched to Belatacept in Long Term Period: Number of Participants With AEs and SAEs

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Day of Switch = the first belatacept infusion day.

Time frame:
Day of Switch (first dose of belatacept ) to last dose plus 56 days, up to Year 6 of the Study
Reported as:
Number · participants
Participants Who Switched to Belatacept in Long Term Period: Number of Participants With AEs and SAEs
participantsBelatacept 5 mg/kg in Participants Switched During LT Period
AEs32
SAEs9

Adverse events

Collected over Date of first dose to 56 days post final dose, up to June 2013 (approximately 80 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belatacept 5 mg/kg—45/83 (54.2%)78/83 (94%)
Calcineurin Inhibitor (CNI)—40/88 (45.5%)74/88 (84.1%)
Belatacept 5 mg/kg in Participants Switched During LT Period—9/38 (23.7%)27/38 (71.1%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
EventBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)Belatacept 5 mg/kg in Participants Switched During LT Period
Urinary tract infectionInfections and infestations8/831/880/38
PyrexiaGeneral disorders5/832/881/38
GastroenteritisInfections and infestations5/832/880/38
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/833/882/38
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/834/881/38
PneumoniaInfections and infestations3/833/880/38
Blood creatinine increasedInvestigations2/833/881/38
Renal failure acuteRenal and urinary disorders1/833/880/38
Cardiac failure congestiveCardiac disorders2/830/881/38
NephropathyRenal and urinary disorders0/830/881/38
Most frequent other events
Showing 10 of 78
Most frequent other events
EventBelatacept 5 mg/kgCalcineurin Inhibitor (CNI)Belatacept 5 mg/kg in Participants Switched During LT Period
DiarrhoeaGastrointestinal disorders36/8325/885/38
CoughRespiratory, thoracic and mediastinal disorders27/8317/883/38
NasopharyngitisInfections and infestations21/8312/883/38
ArthralgiaMusculoskeletal and connective tissue disorders20/837/882/38
Oedema peripheralGeneral disorders20/837/881/38
Urinary tract infectionInfections and infestations19/8310/889/38
HypertensionVascular disorders19/837/884/38
Upper respiratory tract infectionInfections and infestations19/8311/881/38
AnaemiaBlood and lymphatic system disorders18/8312/881/38
HeadacheNervous system disorders16/839/882/38

Baseline characteristics

Participants randomized to a treatment arm.

Age, Continuous
Age, Continuous(years)Belatacept 5 mg/kgCalcineurin Inhibitor (CNI)Total
Mean45.3 ± 13.544.3 ± 13.044.8 ± 13.2
Age, Customized
Age, Customized(participants)Belatacept 5 mg/kgCalcineurin Inhibitor (CNI)Total
18 - 45 years424789
46 - 65 years373673
Greater than (>) 65 years5611
Gender
Gender(Participants)Belatacept 5 mg/kgCalcineurin Inhibitor (CNI)Total
Female182947
Male6660126
08

Study locations

44 sites
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • National Institute Of Transplantation
    Los Angeles, California 90057, United States
  • California Institute Of Renal Research
    San Diego, California 92123, United States
  • Ucsf
    San Francisco, California 94143-0106, United States
  • University Of Chicago
    Chicago, Illinois 60637, United States
  • Pharmacy, First Call Iv
    Kenner, Louisiana 70062, United States
  • Tulane University Hospital & Clinic
    New Orleans, Louisiana 70112, United States
  • University Of North Carolina School Of Medicine
    Chapel Hill, North Carolina 27599-7155, United States
  • Medical College Of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Local Institution
    Capital Federal, Buenos Aires C1425APQ, Argentina
  • Local Institution
    Rosario, Santa Fe 2000, Argentina
  • Local Institution
    Buenos Aires, 1155, Argentina
  • Local Institution
    Cordoba, 5016, Argentina
  • Local Institution
    Santa Fe, S3000EPV, Argentina
  • Local Institution
    Parkville, Victoria 3050, Australia
  • Local Institution
    Bruxelles, 1070, Belgium
  • Local Institution
    Edegem, 2650, Belgium
  • Local Institution
    Curitiba, Parana 80240-000, Brazil
  • Local Institution
    Bonsucesso, Rio De Janeiro 21041-030, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 90035-003, Brazil
  • Local Institution
    Porto Alegre, Rs 90020-090, Brazil
  • Local Institution
    Sao Paulo, 01323-900, Brazil
  • Local Institution
    Edmonton, Alberta T6G 2G3, Canada
  • Local Institution
    Halifax, Nova Scotia B3H 1V8, Canada
  • Local Institution
    Hamilton, Ontario L8N 4A6, Canada
  • Local Institution
    Saskatoon, Saskatchewan S7M 0Z9, Canada
  • Local Institution
    Paris, Cedex 15 75743, France
  • Local Institution
    Toulouse, Cedex 09, France
  • Charite Berlin Mitte
    Berlin, 10117, Germany
  • Local Institution
    Homburg/saar, 66421, Germany
  • Local Institution
    Paladi, Ahmedabad 380007, India
  • Local Institution
    Nadiad, Gujarat 387001, India
  • Local Institution
    Kochi, Kerala 682304, India
  • Local Institution
    Df, Distrito Federal 14000, Mexico
  • Local Institution
    Cuernavaca, Morelos 62448, Mexico
  • Local Institution
    San Luis Potosi, Snl 78240, Mexico
  • Local Institution
    Aguascalientes, 20000, Mexico
  • Local Institution
    Tlalpan, C P, 14080, Mexico
  • Local Institution
    Bydgoszcz, 85-094, Poland
  • Local Institution
    Szczecin, 70-111, Poland
  • Local Institution
    Warszawa, 02-006, Poland
  • Local Institution
    Barcelona, 08026, Spain
  • Local Institution
    Barcelona, 08907, Spain
  • Local Institution
    Valencia, 46017, Spain
09

References and documents

Publications

  • Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Shi R, Di Russo G, Thomas D, Grinyo J. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011 Feb;6(2):430-9. doi: 10.2215/CJN.05840710. Epub 2010 Nov 4. PubMed 21051752 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jun 2009 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 7 years 7 months after primary completion. A results delay was requested in Apr 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2006
First posted
Nov 22, 2006
Start
Jan 2007
Primary completionActual
Jun 2009
CompletionActual
Jun 2013
Results delay requested
Apr 29, 2010
Results first posted
Jan 5, 2017
Last update
Jan 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00402168
Responsible party
Sponsor
First posted
Nov 22, 2006
Start date
Jan 2007
Primary completion
Jun 2009
Completion
Jun 2013
Results posted
Jan 5, 2017
Last update
Jan 5, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion